Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONL1204 in Macula-off Rhegmatogenous Retinal Detachment
NCT03780972Phase 1Completed
- Sponsor
- ONL Therapeutics
- Start
- Oct 2019
- Primary completion
- Aug 2021
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of xelafaslatide in rhegmatogenous retinal detachment (RRD) (4 cohorts), sponsored by ONL Therapeutics. Primary endpoints: Adverse Event Reporting at 24 weeks and Best Corrected Visual Acuity at 24 weeks. Started Oct 2019; status: completed.
02
Drugs
xelafaslatide
03
Conditions
rhegmatogenous retinal detachment (RRD)
Beyond the preview
Go deeper on NCT03780972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03780972.